Skip to main content
. Author manuscript; available in PMC: 2009 Jan 30.
Published in final edited form as: Biol Blood Marrow Transplant. 2008 Jun;14(6):641–650. doi: 10.1016/j.bbmt.2008.03.005

Figure 2.

Figure 2

Engraftment and chimerism. Cumulative incidence of (A) neutrophil and (B) platelet engraftment. Dashed line represents death without engraftment (competing risk). (C) Percentage of donor chimerism at days 28–30 and 56–60. In Seattle, donor chimerism was analyzed from the CD3+ and CD33+ fractions of peripheral blood, whereas in Baltimore donor chimerism was analyzed from whole peripheral blood or bone marrow. Bone marrow samples were not obtained from all evaluable patients.